摘要
目的分析曲美他嗪对接受经皮冠状动脉介入治疗(PCI)的急性心肌梗死(AMI)患者的临床影响。方法选择我院收治的84例接受PCI治疗的AMI患者作为观察对象,对照组接受常规治疗,观察组加用曲美他嗪;比较两组术后左室射血分数(LVEF)、左室短轴缩短率(LVFS)变化及再发心绞痛发生率。结果术后3个月,观察组LVEF、LVFS均高于对照组(P<0.05);观察组再发心绞痛发生率为9.52%,低于对照组26.19%(P<0.05)。结论曲美他嗪可有效改善接受PCI治疗AMI患者的LVEF及LVFS水平,减低再发心绞痛发生率。
Objective To analyze clinical effect of trimetazidine on patients with acute myocardial infarction treated with PCI. Methods 84 cases of PCI-treated patients with AMI admitted to hospital as the observed object,the control group received conventional treatment, observation group were treated with trimetazidine. Postoperative left ventricular ejection fraction（LVEF）,left ventricular fractional shortening（LVFS）and incidence of recurrent angina were compared. Results After 3 months,the observation group of LVEF,LVFS were significantly higher（P 0.05）. The observation group of recurrent angina was 9.52% was significantly lower than the control group 26.19%（P 0.05）. Conclusion Trimetazidine can improve LVEF and LVFS level for PCI-treated patients with AMI,and reduce the incidence of recurrent angina.
出处
《中国卫生标准管理》
2016年第4期86-87,共2页
China Health Standard Management
关键词
急性心肌梗死
经皮冠状动脉介入治疗
曲美他嗪
Acute myocardial infarction
Percutaneous coronary intervention
Trimetazidine
